NCT02389751View on ClinicalTrials.gov

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 10, 2015

Primary Completion Date

July 16, 2019

Study Completion Date

July 16, 2019

Conditions
Gastroesophageal Junction AdenocarcinomaMalignant Neoplasm of the Cervical EsophagusMalignant Neoplasm of the Thoracic EsophagusStage IIA Esophageal Cancer AJCC v7Stage IIB Esophageal Cancer AJCC v7Stage IIIA Esophageal Cancer AJCC v7Stage IIIB Esophageal Cancer AJCC v7Stage IIIC Esophageal Cancer AJCC v7
Interventions
DRUG

Carboplatin

Given IV

DRUG

Ganetespib

Given IV

DRUG

Paclitaxel

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02389751 - Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer | Biotech Hunter | Biotech Hunter